Latest Quark Stories
WATERBURY, Vt., Sept. 23 /PRNewswire/ -- Because travelers to the polar regions cannot try before they buy, Quark Expeditions has produced a number of video guides to provide a visual taste of the adventure that awaits. Two new guides were posted to the polar specialist's website.
A group of University of Toronto high-energy physicists, along with their 3,000 ATLAS colleagues, announced they have broken world records in the search for new particles as the first findings from the Large Hadron Collider (LHC) were presented July 26 in Paris, France.
The Large Hadron Collider (LHC) is giving physicists hopeful candidates in the hunt for the heaviest elementary particle known to science.
FREMONT, Calif., May 4 /PRNewswire/ -- Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that data from the Phase I QPI-1002 (I5NP) DGF Study (NCT#00802347) will be presented at the 2010 American Transplant Congress, taking place May 1-5 in San Diego, California.
DENVER, March 9 /PRNewswire/ -- Virtela, the world's largest independent managed network services company, today announced that Quark Inc. has renewed its contract for global network services with Virtela.
FREMONT, Calif., March 1 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, announced today the dosing of the first patient in a Phase I study of the investigational neuroprotective agent, QPI-1007.
Scientists at the Relativistic Heavy Ion Collider (RHIC), a 2.4-mile-circumference particle accelerator at the U.S. Department of Energy's Brookhaven National Laboratory, report the first hints of profound symmetry transformations in the hot soup of quarks, antiquarks, and gluons produced in RHIC's most energetic collisions.
FREMONT, Calif., Jan. 5 /PRNewswire/ -- Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that the independent Data Safety Monitoring Board ("DSMB") recommended that QPI-1002 (I5NP) continue on to the next phase of clinical testing.
Force of interaction between magnetic particles grows stronger with increasing distance.
FREMONT, Calif., Nov.